Specialty Enzymes Market worth $9.2 billion by 2029 - Exclusive Report by MarketsandMarkets™ [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
to reach USD 9.2 billion by 2029, recording a CAGR of 8.5% from 2024 to 2029 according to a report published by MarketsandMarkets™. The biopharmaceutical industry's rapid expansion, fueled by innovations in biotechnology and personalized medicine, offers significant growth opportunities for the specialty enzymes market. Enzymes are crucial in various biopharmaceutical manufacturing stages, such as protein expression, purification, and modification. They play a vital role in developing biologics, including monoclonal antibodies, vaccines, and gene therapies. With an aging population and a rising incidence of chronic diseases, the demand for biopharmaceuticals is increasing, consequently driving the need for enzymes in biopharmaceutical production. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21682828 Browse in-depth TOC on "Specialty Enzymes Market" 297 – Tables 70 – Figures 306 – Pages Advancements in enzyme engineering have enabled the discov
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Study links GLP-1 drugs, metformin to lower risk of certain cancers [Seeking Alpha]Seeking Alpha
- Diabetes patients using Ozempic, other treatments instead of insulin have lower cancer risk, study finds [FOX News]FOX News
- Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures [Yahoo! Finance]Yahoo! Finance
- Weight-Loss Drugs Linked With Lower Risk of Obesity-Related Cancers [BNN Bloomberg (Canada)]BNN Bloomberg
- Diabetes patients on GLP-1 treatments instead of insulin have lower cancer risk, study shows [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 7/2/24 - Form 6-K
- 6/26/24 - Form 6-K
- 6/24/24 - Form 6-K
- NVO's page on the SEC website